New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization
New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization
复制标题
DOI：
10.1111/liv.13487
复制
发表时间：
2017-12-01
影响因子：
6.7
通讯作者：
Park, Seong Ho
中科院分区：
文献类型：
--
作者：
Kim, Jin Hyoung;Shim, Ju Hyun;Park, Seong Ho
背景和目标：由于其多样性，需要对巴塞罗那临床肝癌（BCLC）中期（BCLC B）进行亚分类。我们评价了Bolondi等人提出的BCLC B亚分类在经动脉化疗栓塞（TACE）治疗患者中的预后能力。此外，我们引入了一个新的亚分类中期肝癌（HCC）通过使用一个新的参数相关的肿瘤负荷方法：在3268例接受TACE作为一线治疗的患者中，821例中期HCC患者纳入本研究。根据Bolondi亚分类，B1、B2、B3和B4分别为208例（25.3%）、529例（64.5%）、43例（5.2%）和41例（5%）。Bolondi系统中的131、132和B3亚类在相邻分期之间的生存率有显著差异，中位生存期分别为51.5、26和14.8个月（均P
Background & Aim: The need for a subclassification of Barcelona Clinic Liver Cancer (BCLC) intermediate-stage (BCLC B) has arisen because of its diversity. We evaluated the prognostic capability of the BCLC B subclassification proposed by Bolondi et al. in patients treated with transarterial chemoembolization (TACE). Furthermore, we introduce a new subclassification for intermediate-stage hepatocellular carcinoma (HCC) by using a new parameter related to tumour burden (up-to-11 criteria).Methods: Of 3268 patients treated with TACE as first-line treatment, 821 patients with intermediate-stage HCC were included in this study.Results: According to the Bolondi subclassification, 208 (25.3%), 529 (64.5%), 43 (5.2%) and 41 (5%) patients were in B1, B2, B3 and B4 respectively. The131,132 and B3 subclasses in the Bolondi system showed significantly different survival between contiguous stages with median survival of 51.5, 26 and 14.8 months, respectively (both P